Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPDL3280A Combined With CDX-1401 in NY-ESO-1+ NSCLC
NCT02495636Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Jul 2015
- Primary completion
- Jul 2017
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab and CDX-1401 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Yale University. Primary endpoint: Objective Response Rate at 8 weeks. Planned start Jul 2015; status: withdrawn.
02
Drugs
atezolizumabCDX-1401
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02495636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02495636.